Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.51 |
| ▸ | KRAS | P01116 | 4/20 | 0.50 |
| ▸ | HINT1 | P49773 | 2/20 | 0.50 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.49 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18955504 | 0.99 | TGM2 (0.54) | TGM2NT5EFUT5KRASHINT1 | |
| SCHEMBL19183426 | 0.93 | NT5E (0.57) | TGM2NT5EFUT5KRASHINT1 | |
| SCHEMBL23710659 | 0.89 | TGM2 (0.55) | TGM2NT5EFUT5KRASHINT1 | |
| SCHEMBL23710656 | 0.89 | TGM2 (0.55) | TGM2NT5EFUT5KRASHINT1 | |
| SCHEMBL8439911 | 0.89 | TGM2 (0.55) | TGM2NT5EFUT5KRASHINT1 | |
| SCHEMBL24772398 | 0.89 | TGM2 (0.55) | TGM2NT5EFUT5KRASHINT1 | |
| SCHEMBL23710657 | 0.89 | TGM2 (0.55) | TGM2NT5EFUT5KRASHINT1 | |
| SCHEMBL24772404 | 0.89 | TGM2 (0.55) | TGM2NT5EFUT5KRASHINT1 | |
| SCHEMBL401415 | 0.88 | TGM2 (0.56) | TGM2NT5EFUT5KRASHINT1 | |
| SCHEMBL9300699 | 0.88 | FUT5 (0.50) | TGM2NT5EFUT5KRASHINT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344118-B2 | Preparation and isolation of 5′ capped MRNA | APPLIED BIOSYSTEMS, LLC (US) | 2013-01-01 | — | — | US | disclosed |
| US-8304529-B2 | Dinucleotide MRNA cap analogs | Life Technologies Corporation (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120156751-A1 | PREPARATION AND ISOLATION OF 5' CAPPED MRNA | APPLIED BIOSYSTEMS, LLC (US) | 2012-06-21 | — | — | US | disclosed |
| US-8093367-B2 | Preparation and isolation of 5′ capped mRNA | APPLIED BIOSYSTEMS, LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100304389-A1 | Preparation And Isolation of 5' Capped mRNA | Life Technologies Corporation (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100261231-A1 | Dinucleotide MRNA CAP Analogs | LIFE TECHNOLOGIES CORPORATION, A DELAWARE CORPORATION (US) | 2010-10-14 | — | — | US | disclosed |
| EP-2049665-A2 | DINUCLEOTIDE MRNA CAP ANALOGS | Applera Corporation (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008016473-A2 | DINUCLEOTIDE MRNA CAP ANALOGS | APPLERA CORPORATION (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100304389-A1 | Preparation And Isolation of 5' Capped mRNA | RNGTT, RNMT, NSUN2 | TGM2 3263/4885NT5E 795/4885FUT5 2808/4885 |
| US-20120156751-A1 | PREPARATION AND ISOLATION OF 5' CAPPED MRNA | RNGTT, RNMT, NSUN2 | TGM2 3263/4885NT5E 795/4885FUT5 2808/4885 |
| US-20100261231-A1 | Dinucleotide MRNA CAP Analogs | RNGTT, RNMT, NSUN2 | TGM2 3982/4885NT5E 343/4885FUT5 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.